Shi-Jie Zou

Design and structure-activity relationship studies of marine-derived indolocarbazoles as potent PIM1 inhibitors for triple-negative breast cancer therapy.

PIM1 has emerged as a compelling target for triple-negative breast cancer (TNBC), which lacks effective treatments. Through integrated virtual screening and in vitro validation, N6 was identified as a potent PIM1-active indolocarbazole lead, although its strong PKC inhibition indicated a limited selectivity window. Str...